Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review

    August 2024 in “ Cureus ”
    Melissa Frangie Machado, Taylor Shunk, Grace Hansen … Joseph De Gaetano
    Studysummary In this study, GLP-1 receptor agonists reduced BMI and improved metabolic and reproductive outcomes in women with PCOS, though the long-term effects remain unclear.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on assets.cureus.com →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Polycystic Ovary Syndrome (PCOS): An Inflammatory, Systemic, Lifestyle Endocrinopathy Journal of steroid biochemistry and molecular biology/˜The œJournal of steroid biochemistry and molecular biology · 2018
    2. Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline The Journal of Clinical Endocrinology and Metabolism · 2013